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Abstract
Background: The COVID-19 pandemic has imposed an enormous burden on health care systems around the
world. In the past, the administration of convalescent plasma of patients having recovered from SARS and severe
influenza to patients actively having the disease showed promising effects on mortality and appeared safe. Whether
or not this also holds true for the novel SARS-CoV-2 virus is currently unknown.
Methods: DAWn-Plasma is a multicentre nation-wide, randomized, open-label, phase II proof-of-concept clinical
trial, evaluating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in
patients hospitalized with COVID-19 in Belgium. Patients hospitalized with a confirmed diagnosis of COVID-19 are
eligible when they are symptomatic (i.e. clinical or radiological signs) and have been diagnosed with COVID-19 in
the 72 h before study inclusion through a PCR (nasal/nasopharyngeal swab or bronchoalveolar lavage) or a chest-
CT scan showing features compatible with COVID-19 in the absence of an alternative diagnosis. Patients are
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randomized in a 2:1 ratio to either standard of care and convalescent plasma (active treatment group) or standard
of care only. The active treatment group receives 2 units of 200 to 250 mL of convalescent plasma within 12 h after
randomization, with a second administration of 2 units 24 to 36 h after ending the first administration. The trial aims
to include 483 patients and will recruit from 25 centres across Belgium. The primary endpoint is the proportion of
patients that require mechanical ventilation or have died at day 15. The main secondary endpoints are clinical
status on day 15 and day 30 after randomization, as defined by the WHO Progression 10-point ordinal scale, and
safety of the administration of convalescent plasma.
Discussion: This trial will either provide support or discourage the use of convalescent plasma as an early
intervention for the treatment of hospitalized patients with COVID-19 infection.
Trial registration: ClinicalTrials.gov NCT04429854. Registered on 12 June 2020 - Retrospectively registered.
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Introduction
Background and rationale {6a}
In December 2019, the Wuhan Municipal Health
Committee identified an outbreak of viral pneumonia
cases of unknown cause. Coronavirus RNA was quickly
identified in some of these patients. This novel
coronavirus has been named SARS-CoV-2, and the dis-
ease was caused by this virus COVID-19. Currently,
there are no approved therapeutic agents available for
coronaviruses [1].
Plasma collected from patients who have recovered
from a SARS-CoV-2 infection can contain antiviral
antibodies detectable through serological testing [2].
It is unclear to what extent these antibodies provide
anti-viral protection, but at least a subset of patients
presents with high titres of neutralizing antibodies, or
with specific potent antibodies irrespective of the titre
[3]. Passing on this plasma to patients newly diag-
nosed with SARS-CoV-2 infection might help them to
clear the infection more rapidly, as it could provide
them with passive polyclonal antibodies and thus re-
duce the antiviral load. The treatment effect of
plasma has already been shown in some viral infec-
tions but has not been studied in patients with SARS-
CoV-2 infection. A recent meta-analysis has shown
that convalescent plasma reduces mortality compared
to standard of care in patients with SARS and severe
influenza infections [4]. Importantly, these studies
were heterogeneous on the timing of plasma adminis-
tration and the threshold on anti-virus antibodies in
convalescent donors. It is particularly successful when
administered early after symptom onset. On the other
hand, convalescent plasma has proven not to be ef-
fective against other viral infections (e.g. Ebola). It
additionally carries a risk of antibody-dependent en-
hancement (ADE), which could result in worsening of
the acute respiratory distress syndrome (ARDS), and
in Argentine haemorrhagic fever convalescent plasma
administration significantly reduced mortality rates,
but was found to be associated with a late neuro-
logical syndrome [5].
Knowledge regarding the immune response to SARS-
CoV-2 infection is rather limited at this point. It seems
that seroconversion occurs within 2 weeks after infec-
tion. Recently, a case series showed that convalescent
plasma possibly had a contributory effect on the clinical
improvement of 5 critically ill patients with SARS-CoV-
2 and acute respiratory distress syndrome [6]. Moreover,
evaluation of 5000 patients having received COVID-19
convalescent plasma in the USA showed the rate of im-
mediate serious adverse events related to the transfusion
to be very low [7], noting that in an open-label setting, a
control group was missing for comparison. Therefore,
more data from controlled trials are urgently needed to
assess the possible role of convalescent plasma during
the COVID-19 pandemic.
This study will therefore evaluate the effect of passive
immunotherapy with convalescent plasma in the
treatment of patients with a newly diagnosed COVID-19
disease requiring hospitalization in a randomized con-
trolled setting. The hypothesis is that early administra-
tion of plasma will help to counter the clinical
deterioration by providing immediate (passive) immunity
when pathology is still mainly driven by viral replication
and hence will prevent the need for mechanical ventila-
tion or death in the first 15 days after randomization. It
is of utmost importance to identify treatment strategies
that reduce the severity of the disease and thereby inten-
sive care unit (ICU) demand during this pandemic with
a high health care burden. Additionally, as strategies of
prolonged distancing are likely to have a negative social
and economic impact, there is a need for efficient and
safe treatment perspectives for COVID-19 patients [8].
The study complies with the recommendations for out-
comes as outlined by the World Health Organization
(WHO) master template protocol [9, 10].
Objectives {7}
The overall objective of the DAWn-plasma study is to
evaluate the clinical efficacy and safety of the addition of
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convalescent plasma to the standard of care in patients
hospitalized with COVID-19.
The primary endpoint of the study is the number of
patients alive without mechanical ventilation at day
15 after hospitalization, with the null hypothesis being
that convalescent plasma will not be effective to
prevent the need for mechanical ventilation or death.
Secondary endpoints are as follows:
– Clinical status of subject at day 15 and day 30 (on a
10-point “WHO progression” ordinal scale):
0. Uninfected, no viral RNA detected
1 Ambulatory, asymptomatic, viral RNA detected
2 Ambulatory, symptomatic, ndependent
3 Ambulatory, symptomatic, assistance needed
4 Hospitalized, mild disease, no oxygen therapy
needed
5 Hospitalized, mild disease, oxygen by mask of
nasal prongs
6 Hospitalized, severe disease, oxygen by NIV or
high flow
7 Hospitalized, severe disease, intubation and
mechanical ventilation (pO2/FiO2 > =150 OR
SpO2/FiO2 ≥ 200)
8 Hospitalized, severe disease, mechanical
ventilation (pO2/FiO2 < 150 OR SpO2/FiO2 <
200) OR vasopressors (norepinephrine > 0.3 μg/
kg/min)
9 Hospitalized, severe disease, mechanical
ventilation pO2/FiO2 < 150 AND vasopressors
(norepinephrine > 0.3 μg/kg/min), OR dialysis
OR ECMO
10 Death, dead
– Cumulative clinical status of subject up to day 15
(on a 10-point ordinal scale): the sum of the daily
clinical status score for days 1 up to 15
– Proportion of patients having been on mechanical
ventilation or are dead at 30 days and 90 days after
randomization
– Status on an ordinal scale assessed daily while
hospitalized and on days 15 and 30
– Time to clinical improvement (number of days from
hospitalization to first 2-point improvement from
highest previously recorded clinical state on the 10-
point ordinal scale)
– Duration of hospitalization
– Duration of supplemental oxygen treatment
– Duration of mechanical ventilation.
– Need for and duration of intensive care stay
– Need for and duration of extracorporeal membrane
oxygenation (ECMO)
– Date and cause of death (if applicable).
– Adverse events graded as severe (SAEs)
– Venous thromboembolism: deep vein thrombosis or
pulmonary embolism
– Transfusion-related side effects such as transfusion-
related acute lung injury, serious allergic transfusion
reactions and transfusion-associated circulatory
overload.
– Correlation between clinical outcome and titre of
anti-SARS-CoV-2 neutralizing antibodies in
transfused plasma units
– Safety of convalescent plasma therapy
– Effect of plasma therapy on quality of life 30 days
after randomization
– Vital signs, being daily highest temperature
measured during hospitalization with a maximum of
14 days after hospitalization and highest flow of
oxygen given (in L/min) daily during hospitalization
with a maximum of 14 days after hospitalization
Trial design {8}
This DAWn-Plasma study is a randomized, open-label
clinical trial to evaluate the safety and efficacy of the
addition of convalescent plasma to standard of care in
hospitalized adult patients diagnosed with COVID-19.
The outcomes of the study protocol are in part based on
the draft master protocol of the WHO for trials that
evaluate the safety and efficacy of investigational thera-
peutics for the treatment of COVID-19 in hospitalized
patients.
This study is a phase II proof-of-concept multicentre
trial. It will compare standard of care vs. standard of
care with convalescent plasma. Since the beginning of
the COVID-19 pandemic, the standard of care (SOC)
has been mostly supportive, in view of the lack of evi-
dence for specific therapies for this novel disease. How-
ever, the standard of care may change during the course
of the study as (inter) national guidelines might be sub-
ject to change as results from randomized controlled tri-
als (RCTs) on anti-viral, anti-inflammatory or anti-
coagulation therapy become available. The clinical out-
comes of this study have been chosen based on the out-
comes of the WHO master template for clinical studies
to allow pooling of the data with other ongoing studies.
The DAWn-Plasma will randomize with a 2:1 alloca-
tion to SOC combined with convalescent plasma versus
SOC.
Methods: Participants, interventions and
outcomes
Study setting {9}
DAWn-Plasma is a multicentre study and will recruit
patients in 25 Belgian hospitals, both academic and non-
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academic. The contributing institutions are mentioned
on clinicaltrials.gov (NCT NCT04429854).
Eligibility criteria {10}
Participants eligible for inclusion in this trial must
meet all of the following criteria:
– Subject (≥ 18 years old) or legally authorized
representative provides informed consent prior to
initiation of any study procedures. When signed
informed consent is not possible (e.g. due to
restrictions to prevent viral transmission), verbal
informed consent in the presence of an independent
witness will be obtained and documented in the
medical files. Signed informed consent will be
obtained as soon as the safety concerns are
mitigated
– Subject (or legally authorized representative)
understands and agrees to comply with planned
study procedures
– Male or non-pregnant female adult ≥ 18 years of age
at time of enrolment
– Patient should be hospitalized
– Has a confirmed diagnosis of SARS-CoV-2 infection,
defined as either:
a Laboratory-confirmed SARS-CoV-2 infection as
determined by PCR, or other commercial or
public health assay in any specimen as diag-
nosed within 72 h prior to randomization, or
b The combination of upper or lower respiratory
infection symptoms (fever, cough, dyspnoea,
desaturation) and typical findings on chest CT
scan and absence of other plausible diagnoses
– Illness of any duration, and at least one of the
following:
a Radiographic infiltrates by imaging (chest X-ray,
CT scan or other), or
b Abnormalities on clinical assessment (evidence
of rales/crackles on exam) and oxygen
saturation (SpO2) ≤ 94% on room air, or
c Requiring supplemental oxygen.
– ABO D typing of the patient should be done at least
once and the result should be known at time of
inclusion.
Participants eligible for this trial must not meet any of
the following criteria:
– Receiving invasive (any mode where a patient has
been intubated endotracheally or via tracheostomy)
or non-invasive mechanical ventilation before or
upon randomization.
– Pregnancy or breastfeeding.
– Any medical condition which would impose an
unacceptable safety hazard by participation to the
study, as deemed by the investigator.
– Patients with a history of a documented grade 3
allergic reaction after the administration of fresh
frozen plasma (i.e. systemic reaction with
cardiovascular and/or respiratory involvement).
– Patients that have treatment restrictions that
exclude mechanical ventilation and/or endotracheal
intubation.
Who will take informed consent? {26a}
Potential participants are screened on the emergency
ward or upon arrival at the COVID-ward. Accordingly,
an emergency physician or a supervising physician at the
COVID-ward that is trained in the protocol will first as-
sess the patient’s interest in the study. In case a patient
is interested to participate, the investigators of the
DAWn-study team again check the eligibility criteria
and contact the patient to provide more information and
obtain an informed consent.
The consent form includes a short and
comprehensible summary of the rationale of the trial,
the trial design and the study drug. This is followed by
an elaborate form, where all study-related procedures,
clinical data collection (for instance clinical scores and
vital signs), biosample collection (for instance blood
draws and nasal swabs) and the potential risks (potential
adverse events) and benefits (potential positive effect of
the intervention, contribution to knowledge production)
from the study are explained. Data management and
ethical approval are detailed, as well as the insurance
policy. The investigator also verbally explains this con-
sent form and is available for questions before the pa-
tient is asked to sign the consent form. A copy of the
informed consent form is attached to this manuscript as
Supplementary Material.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
In case no DAWn-investigator is on duty on the
COVID-ward at the time of inclusion, obtaining a writ-
ten consent within the time window of inclusion, but
without wasting extra personal protective equipment is
difficult. In order to avoid this, we were granted permis-
sion by the ethical committee to do the first contact be-
tween the DAWn-investigator and patient by telephone.
The consent form is read and illustrated by the investi-
gator on the phone, and the patient gives verbal consent.
An independent witness is in the presence of the patient
or the investigator to confirm that the patient has under-
stood the study procedures and agrees with them. Data
collection, randomization and, in case the patient is ran-
domized to the active treatment group, administration
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of the plasma can then already start awaiting the signed
version of the written informed consent form that will
be sent to the investigator by the patient at a point in
time when it is safe to do so.
Interventions
Explanation for the choice of comparators {6b}
The addition of convalescent plasma to standard of care
will be compared to standard of care treatment for
patients hospitalized with COVID-19. No active com-
parator drug is imposed by the trial.
Intervention description {11a}
Screening/baseline
Demographic parameters will be obtained. Medical
history will be obtained as part of routine clinical care.
Concomitant medication will be reviewed using the
electronic medical files. A first blood group
determination should be done upon hospitalization of
the patient to facilitate fast plasma administration
following randomization. A nasopharyngeal swab for
viral qPCR analysis is taken at baseline, on day 0 (+/− 2)
(Fig. 1).
Randomization
To ensure the integrity of the trial, a randomization
procedure through the software REDCap has been
established, generated by the data management unit of
the clinical trial centre Leuven. Patients from all centres
will be randomized centrally, in a 2 (active treatment
group) to 1 (SOC) ratio.
Administration of trial product
In case the patient is randomized to the active treatment
group, convalescent plasma (2 units of 200 to 250 mL)
will be administered within 12 h after randomization,
with a second administration (2 units of 200 to 250 mL)
24 to 36 h after ending the first administration. Plasma
should not be transfused at the usual speed of 30 to 45
min but should be administered at a maximal speed of
50 to 100 mL per hour, in order to reduce the risk of
volume overload. Parameters will be monitored during
the administration of plasma according to good clinical
practice.
COVID-19 convalescent plasma (CCP) donors are
recruited in a population of patients that were infected
with COVID-19 and recovered. At least 28 days should
have passed since full recovery and disappearance of the
symptoms. Potential donors must at least fulfil national
legal requirements for eligibility of donors to donate
blood or plasma. The Blood Establishment qualify dona-
tions from donors with neutralizing antibody titres
greater or equal to 1/320 as appropriate for this study.
Daily assessments until discharge
The following information will be retrieved daily until
the day the patient is discharged from the hospital: (1)
vital signs including SpO2, (2) clinical data for
assessment of study outcomes and (3) adverse event
evaluation. Serious adverse events and adverse events
grade IV will be collected even when these are not part
of the endpoints of the study.
Visit at day 15 (+/− 2), 30(+/− 3) and 90 (+/− 5)
In case the patient is no longer hospitalized on the days
a clinical assessment is needed for evaluation of the
primary and secondary endpoints, these visits can be
replaced by telephone contacts with the patient
enquiring about their status.
Additional sampling
The study includes two optional samples:
Fig. 1 Overview of the study interventions
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– At baseline: on day 0 (+/− 2): blood samples for the
assessment of immunoparesis against SARS-CoV-2
and antibody clearance. This blood samples should
be collected before the first infusion of convalescent
plasma. Samples will be stored locally and shipped
in batches to the central reference lab. The practical
details of local storage and shipment can be found in
the lab manual.
– On day 6 (+/− 2): blood samples for the assessment
of immunoparesis against SARS-CoV-2 and antibody
clearance. Samples will be stored locally and shipped
in batches to the central reference lab. The practical
details of local storage and shipment can be found in
the lab manual.
The study includes a sample to be taken, when
feasible:
– Viral qPCR (nasopharyngeal swab) at day 6 (+/− 2).
Criteria for discontinuing or modifying allocated
interventions {11b}
Participants may voluntarily discontinue trial treatment
and/or prematurely end their participation in the trial
for any reason at any time. In such case, the investigator
must make a reasonable effort to contact the participant
(e.g. via telephone, e-mail, letter) in order to document
the primary reason for this decision.
The investigator may also decide at any time during
the course of the trial, to temporarily interrupt or
permanently discontinue the trial treatment if it is
deemed that continuation would be detrimental to, or
not in the best interest of the participant.
Similarly, the sponsor, Ethics Committee (EC) or
authorized regulatory authority can decide to halt or
prematurely terminate the trial when new information
becomes available whereby the rights, safety and well-
being of trial participants can no longer be assured,
when the integrity of the trial has been compromised, or
when the scientific value of the trial has become obsolete
and/or unjustifiable.
Circumstances requiring premature treatment
interruption or discontinuation of the trial, include but
are not limited to: (1) safety concerns related to blood
product or unacceptable intolerability (potentially life-
threatening transfusion reaction during plasma infusion),
(2) trial participation while in violation of the inclusion
and/or exclusion criteria and (3) pregnancy or the
intention of becoming pregnant. In any such case of
early trial termination and/or treatment interruption/
discontinuation, the investigator will continue to closely
monitor the participant’s condition and ensure adequate
medical care and follow-up. Additionally, these patients
will continue to be followed for the primary outcome
and their data will be included in intention-to-treat
analyses.
For participants whose status is unclear because they
fail to appear for trial visits without stating an intention
to discontinue or withdraw, the investigator must make
every effort to demonstrate “due diligence” by
documenting in the source documents which steps have
been taken to contact the participant to clarify their
willingness and ability to continue their participation in
the trial (e.g. dates of telephone calls, registered letters).
A participant should not be considered lost to follow-up
until due diligence has been completed.
Strategies to improve adherence to interventions {11c}
For the administration of convalescent plasma, a specific
standard operating procedure (SOP) was created.
Detailed information on administration is provided
within the hospital’s electronic system and is displayed
when nurses administer the plasma. Permanent remote
assistance is available as investigators are standby 24 h a
day, 7 days a week.
Relevant concomitant care permitted or prohibited
during the trial {11d}
Patients will receive the standard of care treatment for
COVID-19 as pointed out by national and international
guidelines at the time of diagnosis. Any drugs or proce-
dures required in that context are permitted. The ad-
ministration of any investigational medicinal products
(IMPs) other than plasma is not allowed. No other drugs
or procedures are prohibited during this trial.
Provisions for post-trial care {30}
As per European legislation, the sponsor has a full
insurance that covers the costs of potential harms.
Outcomes {12}
The primary outcome of the study is the number of
patients alive without mechanical ventilation at day 15
after hospitalization. The primary objective of the study
is to avoid further clinical decline by administering
convalescent plasma to hospitalized patients early after
symptom onset to provide immediate (passive)
immunity. The hypothesis is that early administration of
plasma will help to counter the clinical deterioration
when pathology is mainly driven by viral replication and,
hence, will prevent the need for mechanical ventilation
or death in the first 15 days after randomization. The
null hypothesis is that convalescent plasma will not be
effective to prevent the need for mechanical ventilation
or death.
Secondary outcomes are defined in the “Outcomes”
section of this protocol (cfr. supra).
Exploratory outcomes are as follows:
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– Qualitative and quantitative PCR for SARS-CoV-2 in
(nasopharyngeal) swab on day 6 (when feasible)
– Comparing clinical efficacy of convalescent plasma
in patients that already had anti-COVID19 anti-
bodies before the administration of the plasma com-
pared with patients that did not. These results will
not be available real-time but are subject to a post
hoc analysis
Participant timeline {13}
Table 1 shows the participant timeline.
Sample size {14}
Despite rapid dissemination of data from clinical case
series and some early-stage clinical trials, detailed infor-
mation about the course of the disease is limited in this
stage of the COVID-19 pandemic. The sample sizes pre-
sented here are only illustrative.
Furthermore, in the absence of treatments with a
known benefit, rapid changes in standard of care are to
be expected and important signs of a benefit or harm of
a treatment under investigation will require rapid
reporting. Safety issues will be continuously monitored
by a Data and Safety Monitoring Committee (DSMB),
and if at any stage evidence emerges that any one
treatment arm is definitely inferior it can be decided that
the study will be discontinued. Conversely, if good
evidence emerges while the trial is continuing that some
other treatment(s) should also be being evaluated, then
it can be decided that one or more extra arms or strata
will be added while the trial is in progress.
Around 20% of patients hospitalized for a SARS-CoV-
2 infection are admitted to the ICU with respiratory fail-
ure. When admitted to the ICU, 80% of these patients
need mechanical ventilation. With the administration of
convalescent plasma as early as possible, we hope to de-
crease the proportion of patients who have a clinical de-
cline and need ICU support. We assume by providing
passive immunity with convalescent plasma, we are able
to reduce the proportion of patients admitted to the
ICU from 20 to 15%. Furthermore, we assume that, even
when admitted to ICU, the need for mechanical ventila-
tion will be reduced from 80 to 50%. With a power of
0.8, a delta of 8.5% (16% in the control group and 7.5%
in the invention group), a randomization ratio of 2:1 and
an alpha of 0.05, sample size estimates to detect a differ-
ence between both groups is 483 patients with 322 pa-
tients and 161 patients in the intervention and standard
of care group, respectively (using a Pearson chi-square
test for proportion difference). We therefore propose
these numbers as a pragmatic initial sample size.
Outcomes are in line with other studies with
convalescent plasma that are being set up or just started
recruitment in other countries. A huge effort is now
made on an international level to combine all results of
other studies studying the added value of convalescent
plasma. All results will be made available in real-time in
an international database. This allows to make sound
scientific conclusions in a limited time frame. At the
time this international database is available, an amend-
ment will be made to the institutional review board.
Recruitment {15}
All patients diagnosed with COVID-19 are screened at
the emergency ward or upon arrival at the COVID-
ward. An emergency physician or a physician at the
COVID-ward that is trained in the protocol will first as-
sess the patient’s interest in the study. In case a patient
is interested to participate, the investigators of the
DAWn-study team again check the eligibility criteria
and contact the patient to provide more information and
obtain informed consent. By doing so, every patient that
gets hospitalized with COVID-19 is screened upon
admission.
Assignment of interventions: allocation
Sequence generation {16a}
A randomization procedure through a computerized
system (REDCap) has been established, generated by the
data management unit of the clinical trial centre Leuven,
which ensures the integrity of the trial.
Concealment mechanism {16b}
In this open-label study, patients are allocated in order
of diagnosis using a computerized system (REDCap) ap-
plying an unknown allocation sequence.
Implementation {16c}
The investigators will randomize the patients using a
computerized system (REDCap).
Assignment of interventions: blinding
Who will be blinded {17a}
The study is an open-label study, the study participants
and clinical staff are not blinded.
Procedure for unblinding if needed {17b}
N/A.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Source data will be collected and recorded in the
participant’s files/medical records. Worksheets may be
used for capturing some specific data in order to
facilitate the completion of the electronic case report
form (eCRF). Any such worksheets will become part of
the participant’s source documentation and will be filed
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together with or as part of the medical records (during
but also following completion of the trial).
It remains the responsibility of the Investigator to
check that all data relating to the trial, as specified in the
trial protocol, are entered into the eCRF in accordance
with the instructions provided and that the forms are
filled out accurately, completely and in a timely manner.
eCRFs are provided by the sponsor for each
participant. A copy of the eCRF is attached to this
manuscript as Supplementary Material. The trial data
will be transcribed from the source records (i.e.
participant’s medical file or trial-specific source data
worksheets) into an eCRF by trial staff. Transcription to
the eCRF will be done as soon as possible during
hospitalization or after a participant visit or telephone
contact and in a pseudonymized manner using a unique
identifier assigned by the sponsor.
Plans to promote participant retention and complete
follow-up {18b}
If patients are discharged from the hospital, they may be
called at certain time points in order to have sufficient
Table 1 Participant timeline
























Review COVID-19 criteria X
In- and exclusion criteria X
ABO D typing1 X
Study intervention
Randomization X
Administration of Plasma X X
Study procedures
Vital signs including SpO2 X Daily until
discharge
Clinical data collection X Daily until
discharge
Targeted medication review X Daily until
discharge
Targeted adverse event




Evaluation by telephone X X X
Laboratory
CRP, haematology, chemistry,











Blood for COVID-19 antibody
titre testing and immunoparesis
(optional) 2
X X
Quality of life (QoL) scoring3 X X X
1ABO D typing has to be performed twice at two different, independent time points and the two ABO D results have to be identical before the blood institution
can release the plasma units. Before randomization, the ABO D typing should be done at least once and the result should be known
2One serum tube of 10mL and one EDTA tube of 10 mL. This blood is drawn if feasible and in sites that agree to participate
3QoL scoring using the EQ-5D-5L questionnaire. QoL scoring at day+ 30 is optional if the patient is still hospitalized; if the patient is at home at day+ 30, scoring
will be done by telephone call
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data for all endpoints previously described. The same
data will be collected from participants where a protocol
violation has occurred.
Data management {19}
Data are stored and pseudonymized in the REDCap
system allowing secure and General Data Protection
Regulation (GDPR)-compliant data handling. The trial
data manager will perform extensive consistency checks
on the received data. Queries will be issued in case of
inconsistencies in accordance with internal procedures. A
Data Management Plan (DMP) will be developed to map
data flows, data validation measures that will be taken,
how (interim) database lock(s) will be managed and, as
applicable, the role and responsibilities of the DSMB.
Confidentiality {27}
The trial will be conducted in compliance with the
requirements of the EU GDPR 2016/679, the relevant
Belgian laws implementing the GDPR including the
Belgian Privacy Act of 30 July 2018 on the protection of
privacy in relation to the processing of personal data.
Any collection, processing and disclosure of personal
data, such as participant health and medical information,
is subject to compliance with the aforementioned
personal data protection laws (cfr. Data Processing
Annex (DPA) in Appendix I of the protocol provided as
an appendix to this paper). In case personal data is
transferred outside the European Economic Area,
safeguards will be taken to ensure that appropriate
protection travels with the data in accordance with the
GDPR.
Any personal data shall be treated as confidential at all
times including during collection, handling and use or
processing and the personal data (including in any
electronic format) shall be stored securely at all times
and with all technical and organizational security
measures that would be necessary for compliance with
EU and national data protection legislation (whichever is
more stringent). The sponsor shall take appropriate
measures to ensure the security of all personal data and
guard against unauthorized access thereto or disclosure
thereof or loss or destruction while in its custody.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
The following analyses will be performed on samples
collected during the trial:
– Immunoparesis: Serum samples from day 0
(baseline) and day 6 are temporarily stored at the
study sites and sent in batch to four collaborating
laboratories: REGA institute Leuven, Sciensano,
University of Liège and Institute of Tropical
Medicine Antwerp. A CPE-based neutralization test
is performed on serum to detect SARS-CoV-2 neu-
tralizing antibodies, as the assay is considered the
standard for coronavirus serologic analysis.
– Quantitative PCR analysis: Qualitative PCR analysis
(nasopharyngeal swab or bronchoalveolar lavage) is
performed on day 0 and day 6 as mentioned before.
The rest medium of this is temporarily stored at the
study sites and consequently sent in batch to the
biobank of the central study site (UZ Leuven) to
perform quantitative PCR analysis at a later stage.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
This is an open-label controlled randomized trial testing a
superiority hypothesis with a two-sided type I error rate of
0.05. In this exploratory study, secondary hypotheses will
be tested in a non-hierarchical way. These will be described
according to the appropriate summary statistics (e.g., pro-
portions for categorical data, means with 95% confidence
intervals for continuous data, median for time-to-event
data). A statistical analysis plan (SAP) will be developed
and filed with the study sponsor prior to database lock.
The study design allows standard care or best supportive
care to be changed in function of the Belgian Sciensano
recommendations for treating COVID-19. Standards of
care may rapidly change in pandemic situations, even dur-
ing the enrolment of study participants. For differences be-
tween centres, or new recommendations for standard care,
statistical adjustments will be made in the analysis.
The following analysis sets will be defined:
– Full analysis set (FAS) and modified-intention-to-
treat (mITT, an intention-to-treat analysis allowing
for justified exclusion of some randomized
individuals, e.g. in the case of post-randomization
considered ineligibility): The FAS will include all
randomized patients according to their randomized
treatment. Patients randomized to the interventional
group will be excluded if they did not receive any
dose of study blood product. The FAS will be used
for the evaluation of all efficacy endpoints. mITT
will be applied as primary analysis and FAS as
secondary analysis.
– Safety set (SS): The SS will include all patients who
were randomized according to their actual treatment.
Patients randomized to the interventional group who
did not receive any study treatment will be included in
the SOC group. The SS will be used for the evaluation
of all safety parameters.
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1 Analysis of the primary efficacy endpoint: number
of patients alive without mechanical ventilation at
day 15 after randomization.
The null hypothesis tested is that the proportion of
patients that meet the primary endpoint is equal in the
standard of care and experimental treatment arm. The
alternative hypothesis is that those proportions are
different. The primary analysis will be based on a
Cochran–Mantel–Haenszel test, stratified for centre. As
a secondary analysis, a logistic mixed model will be used
with random centre effect and random centre by
treatment interaction, allowing to study how the
treatment effects vary between centres.
2. Analysis of the secondary endpoint(s)
For the analysis of the WHO outcome, used as a
sensitivity analysis, we use a cumulative clinical severity
score, based on the 10-category ordinal scale, for the
first 15 days (or other time points, based on the blinded
interim analysis as described above). This score is calcu-
lated by adding the daily severity score (highest score for
that day) for each day from day 1 to day 15, thus provid-
ing a cumulative measure of disease severity during the
course of the disease. Appropriate methods will be used
to account for patients for whom the status is not
known for the full 15 days.
The null hypothesis being tested is that the mean
cumulative clinical severity score during the first 15 days
is the same for the standard of care and experimental
treatment arms. Because means of summed scores over
a number of days are expected to be symmetrically
distributed, we will use a t test to compare the mean
cumulative clinical severity score on day 15 between the
treatment and the standard of care group. The
treatment effect will be estimated by the difference in
mean scores between the treatment groups.
As a co-WHO outcome, according to the WHO
suggestions, we will use the ordinal scale to estimate
a proportional odds model. For this model, the pri-
mary hypothesis test will be based on a test of
whether the common odds ratio for treatment is
equal to one. For large sample sizes, the hypothesis
test is nearly the same as the Wilcoxon rank-sum
test.
Therefore, the procedure produces a valid p value
regardless of whether the proportional odds model is
correct. Nonetheless, estimation and confidence
intervals do require the model to be correct.
Accordingly, we will evaluate model fit using a
goodness-of-fit likelihood ratio test. A stratified
hypothesis test to account for baseline severity of the
disease will be used. The treatment effect will be esti-
mated by the common odds ratio obtained from the
proportional odds logistic regression model.
– All-cause mortality rates will be estimated by the
treatment group using the Kaplan-Meier method.
The resulting Kaplan-Meier curves will be compared
using a log-rank test. The treatment effect will be
estimated by the hazard ratio using a Cox
regression.
– Time-to-event parameters with competing risk (time
to clinical improvement, composite cardiac
endpoint): event rates will be estimated using
cumulative incidence functions (CIF), the resulting
CIF curves will be compared using Gray’s test. The
treatment effect will be estimated by the
subdistribution hazard ratio.
– Duration of hospital and ICU stay: both parameters
will be analysed as time-to-event parameters with
competing risk, whereby the event of interest is
discharge from hospital/ICU and the competing risk
is hospital/ICU death.
– Continuous normally distributed variables (e.g. QTc)
will be analysed using a 2-sample t test. Treatment
effects will be estimated by the difference in mean
values between the groups. If applicable, changes
from baseline will be calculated. Comparisons be-
tween treatment groups will be done by performing
an analysis of covariance (ANCOVA) on the post-
baseline value, using the baseline value as a
covariate.
– Continuous non-normally distributed variables
(clinical status, National Early Warning Score
(NEWS) score, duration of supplemental oxygen,
duration of mechanical ventilation) will be analysed
using a Wilcoxon rank-sum test. Change in ordinal
scale at specific time points will be compared using
Wilcoxon rank-sum tests.
Missing data procedures will be described in the SAP.
3. Safety analyses
Adverse events (AE) will be analysed univariately and
as a composite endpoint. Time-to-event methods will be
used for death and the composite endpoint. Each ad-
verse event will be counted once for a given participant
and graded by severity and relationship to COVID-19 or
study intervention.
Adverse events leading to premature discontinuation
from the study intervention and serious treatment-
emergent AEs will be described as part of the primary
publication of the study results.
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4. Baseline descriptive statistics
Baseline characteristics will be summarized by
treatment arm. For continuous measures, the mean and
standard deviation will be summarized. Categorical
variables will be described by the proportion in each
category (with the corresponding sample size numbers).
Interim analyses {21b}
No formal interim analysis will be planned. A DSMB
will monitor ongoing results to ensure patient well-
being and safety as well as study integrity. The
DSMB, containing one statistician, will have the op-
portunity to ask for data, to require analyses or to
compare Belgian trial results with results available
from other countries. The DSMB will be asked to
recommend early termination or modification only
when there is clear and substantial evidence of a
safety issue.
Early analyses include monitoring enrolment, baseline
characteristics and follow-up rates throughout the
course of the study by the study team. Analyses will be
conducted blinded to treatment assignment by the
DSMB.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
Subgroup analyses for the primary and selected
secondary outcomes will evaluate the treatment effect
across the following subgroups: duration of symptoms
prior to enrolment, age groups, disease severity at
baseline, presence of COVID-19 antibodies prior to con-
valescent plasma administration and co-morbidities. A
forest plot will display confidence intervals across sub-
groups. Interaction tests will be conducted to determine
whether the effect of treatment varies by subgroup.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
In the case of missing data, multiple imputation will be
performed. The exact number of iterations will be set
when it will be clear how many data are missing. We do
not expect much data to be missing as this is a
prospective trial with dedicated data management.
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
The full protocol is available as an appendix to this
paper. At this time no public access to the patient
dataset is planned.
Oversight and monitoring
Composition of the coordinating Centre and trial steering
committee {5d}
The DAWn-Plasma trial steering committee consists of
specialists in the field of haematology, infectiology, re-
spiratory diseases, intensive care, general internal medi-
cine, haemovigilance and biostatistics. The committee is
composed in such a way that the different key role play-
ing institutions of the DAWn-Plasma trial are
represented.
Composition of the data monitoring committee, its role
and reporting structure {21a}
Monitoring of the trial will be performed by qualified
individuals (independent from the site trial staff)
according to the monitoring plan. The sponsor and
investigator/participating site will permit direct access to
the trial data and corresponding source data and to any
other trial-related documents or materials to verify the
accuracy and completeness of the data collected.
The data safety and monitoring committee (DMC)
consists of 6 qualified members, independent from the
site trial staff. Their scientific independence is assured
through a DMC charter and terms of reference. Because
of the exceptional circumstances, the DMC is part of UZ
Leuven.
DMC will monitor ongoing results to ensure patient
well-being and safety as well as study integrity. It will be
asked to recommend early termination or modification
only when there is clear and substantial evidence of a
safety issue.
Adverse event reporting and harms {22}
Investigators will seek information on AEs during each
patient contact. All events, whether reported by the
patient or noted by trial staff, will be recorded in the
patient’s medical record and the (e) CRF within a
reasonable time after becoming aware. If available, the
diagnosis should be reported on the AE form, rather
than the individual signs or symptoms. If no diagnosis is
available, the investigator should record each sign and
symptom as individual AEs.
Frequency and plans for auditing trial conduct {23}
The investigator will permit direct access to trial data
and documents for monitoring, audits and/or
inspections by authorized entities such as but not
limited to: the sponsor or its designees and competent
regulatory or health authorities. As such, eCRFs, source
records and other trial-related documentation (e.g. the
Trial Master File, pharmacy records) must be kept
current, complete and accurate at all times.
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Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
As per good practice, trial participants will be informed
of significant changes during the trial. Yearly updates
will be given to the ethical committee.
Dissemination plans {31a}
The primary paper will be published in a peer-reviewed
journal and presented at international meetings.
Discussion
The administration of convalescent plasma has
previously proven to be a promising strategy in
enhancing patients’ immune response to infectious
diseases such as severe influenza and SARS. Whether or
not this approach could help avoiding serious
complications from SARS-CoV-2 infection is currently
unknown, and uncertainty exists regarding the most ap-
propriate timing and dose of convalescent plasma to be
administered in that setting. In this trial, we have chosen
the administration of a high dose of CCP, with 4 units
being administered within a 36-h timeframe. Addition-
ally, donors are required to have high neutralizing anti-
body titres of at least 1/320, which is a demanding and
strict requirement because we hypothesize that high
antibody titres are important for the efficiency of the
CCP-treatment. The titres reached in the patient receiv-
ing the plasma are monitored throughout the study.
Moreover, in order to optimize the interpretability of re-
sults coming from different sites, a study in which the
four laboratories performing the neutralization tests on
serum for the DAWn-Plasma trial are correlating their
results is currently ongoing. A high quality of the plasma
used in this trial is therefore ensured and carefully moni-
tored. Additionally, full characterization of CCP will be
performed later on, to further investigate the specific
role of neutralizing antibodies and non-neutralizing anti-
bodies in the plasma.
With regards to the timing of treatment, the DAWn-
Plasma investigators have chosen to administer the con-
valescent plasma in an early time-frame after diagnosis
and hospitalization for COVID-19. Randomization is
allowed for up to 72 h after COVID-19 diagnosis, and
the first units are administered within 12 h after
randomization to the active treatment arm. A CCP-unit
is infused over 3 h, which was deemed the safest among
standard procedures of plasma transfusion by the inves-
tigators of this trial.
This trial is a prospective randomized controlled trial.
In the past, non-randomized convalescent plasma trials
have been carried out for other viral infections [11, 12],
so there is an urgent need for prospective randomized
trials to prove the efficacy (or not) of convalescent
plasma therapy. Currently, patients are being enrolled in
20 sites with a possibility of expanding to a total of 25
sites. The participating hospitals are geographically
spread across the country. This will help in faster accrual
of the number of patients required for this study and is
an advantage especially in the context of the expected
evolution of the pandemic, with local flare-ups of SARS-
CoV-2 infection rates. Also, convalescent plasma can be
obtained from local donors and the Red Cross (both
Rode Kruis-Vlaanderen and Croix-Rouge Service du
Sang) has long-standing experience with the distribution
of blood products to different sites.
At UZ Leuven, this trial is coordinated together
with other trials of the DAWn consortium in a
central command unit. Qualified personnel, existing
of both Medical Doctors and Clinical Trial Assistants,
screen newly diagnosed and hospitalized patients for
eligibility criteria for the DAWn trials. They are
trained in the protocols and coordinate the inclusion
of patients based on procedures agreed upon between
investigators beforehand. This central command unit
is a useful structure to ensure continuous availability
of trained personnel. Not only is the collaboration
between investigators within UZ Leuven well-
coordinated, the collaboration of the DAWn-Plasma
team with the different parties involved -such as the
different participating sites, the blood establishments
and the laboratories- is also coordinated on a high
level and runs efficiently.
The limitations of the study are the following: (1) the
DAWn-Plasma trial is an open-label study. (2) The in-
formed consent of the patient is not obtained through
standard procedures because of safety measures that re-
strict the transfer of paper documents out of the
COVID-19 ward. However, a procedure has been put in
place to ensure the patient is fully informed and his/her
verbal consent is witnessed by an independent person,
and written informed consent is additionally sent to the
investigators later on. (3) Another possible limitation of
this study is that the novelty of this disease results in
rapidly changing guidelines on the standard of care for
treating these patients and that this might influence the
DAWn-Plasma trial and potentially impose adaptations
in the study protocol. (4) And lastly, the unpredictability
of the COVID-19 pandemic leads to uncertainties re-
garding inclusion rates for this study, as well as to un-
certainty regarding event rates in case good treatment
strategies would become available.
Trial status
The first patient was included on the 2nd of May 2020.
We expect enrolment to be completed by July 2021,
provided that the pandemic remains active in Belgium.
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